What is HC Wainwright’s Forecast for Prothena Q4 Earnings?

Prothena Co. plc (NASDAQ:PRTA) – Investment analysts at HC Wainwright issued their Q4 2025 earnings estimates for Prothena in a research report issued to clients and investors on Friday, February 21st. HC Wainwright analyst A. Fein expects that the biotechnology company will earn ($0.58) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $48.00 price objective on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.06). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The business had revenue of $2.12 million for the quarter, compared to the consensus estimate of $7.53 million.

PRTA has been the subject of a number of other research reports. Oppenheimer boosted their price objective on Prothena from $58.00 to $62.00 and gave the company an “outperform” rating in a research report on Friday, February 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Prothena in a report on Friday, February 21st. Chardan Capital reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Prothena in a report on Friday, February 21st. StockNews.com raised shares of Prothena from a “sell” rating to a “hold” rating in a research note on Monday. Finally, Bank of America decreased their target price on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $45.83.

Prothena Trading Down 3.9 %

NASDAQ:PRTA opened at $14.63 on Monday. The stock has a 50 day moving average of $14.40 and a 200-day moving average of $16.68. The firm has a market capitalization of $787.23 million, a PE ratio of -6.36 and a beta of 0.08. Prothena has a 52 week low of $11.70 and a 52 week high of $31.03.

Hedge Funds Weigh In On Prothena

A number of institutional investors and hedge funds have recently bought and sold shares of PRTA. Virtus ETF Advisers LLC lifted its stake in shares of Prothena by 19.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 833 shares during the period. Headlands Technologies LLC raised its holdings in Prothena by 196.5% during the fourth quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 4,858 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in Prothena in the fourth quarter worth approximately $145,000. Purkiss Capital Advisors LLC bought a new position in Prothena during the 4th quarter valued at $149,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Prothena by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 1,065 shares during the period. Institutional investors own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.